Study in Adolescents/Adults to Evaluate Non-inferiority&Persistence up to 5 Years of GSK Bio MenACWY Conjugate Vaccine

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT00356369
First received: July 25, 2006
Last updated: March 28, 2013
Last verified: July 2012
  Purpose

Meningococcal disease is mostly caused by N. meningitidis of serogroups A, B, C, W-135, Y. Meningococcal polysaccharide-conjugate vaccines have the advantage to induce a T-cell dependant immune response while the existing polysaccharide vaccines induce a T-cell independent response, i.e. with no immune memory response. GSK Biologicals has developed a combined Men ACWY conjugate vaccine intended to protect against meningococcal disease due to serogroups A, C, W-135 and Y. In the vaccination phase of this study, the new MenACWY-TT conjugate vaccine will be evaluated in adolescents and adults using Mencevax™ ACWY as control. In the long-term follow-up phase (extension phase) of the study, the long-term protection offered by the new MenACWY-TT conjugate vaccine will be assessed up to five years after the vaccination in adolescents and adults using Mencevax™ ACWY as control. This protocol posting deals with objectives & outcome measures of both the primary & extension phases.


Condition Intervention Phase
Meningococcal Infection
Biological: meningococcal ACWY (vaccine)
Biological: Mencevax™ ACWY
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: Phase IIb Primary Vaccination Study to Evaluate Non-Inferiority & Persistence of the Immune Response of GSK Biologicals' MenACWY Conjugate Vaccine (Intramuscularly) vs Mencevax ACWY (Subcutaneously) to Healthy Subjects (11-55 Years of Age)

Resource links provided by NLM:


Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Vaccine response to meningococcal antigens [ Time Frame: One month post vaccination ] [ Designated as safety issue: No ]
  • Occurrence of any grade 3 systemic symptoms [ Time Frame: During the 4-day follow-up period after vaccination ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Meningococcal rSBA titres [ Time Frame: Prior to, 1 month and 1, 2, 3, 4 & 5 years after vaccination ] [ Designated as safety issue: No ]
  • Anti-meningococcal polysaccharide antibody concentrations [ Time Frame: Prior to, 1 month and 1, 2, 3, 4 & 5 years after vaccination ] [ Designated as safety issue: No ]
  • Anti-tetanus toxoid seroprotection and antibody concentrations [ Time Frame: Prior to and 1 month after vaccination ] [ Designated as safety issue: No ]
  • Occurrence of solicited local and general symptoms [ Time Frame: During the 4-day follow-up period after vaccination ] [ Designated as safety issue: No ]
  • Occurrence of unsolicited symptoms [ Time Frame: Up to 1 month after vaccination ] [ Designated as safety issue: No ]
  • Occurrence of serious adverse events (including meningococcal diseases) [ Time Frame: Up to 6 months after vaccination ] [ Designated as safety issue: No ]
  • Occurrence of specific adverse events of rash, new onset of chronic illness(es) and conditions prompting emergency room visits and physician office visits not related to common illnesses [ Time Frame: Up to 6 months after vaccination ] [ Designated as safety issue: No ]
  • Occurrence of serious adverse events (including meningococcal diseases) related to vaccination and any event related to lack of vaccine efficacy [ Time Frame: From 6 months up to 5 years after vaccination ] [ Designated as safety issue: No ]

Enrollment: 500
Study Start Date: December 2006
Study Completion Date: May 2012
Primary Completion Date: May 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Group A
Subjects receiving GSK Biologicals' meningococcal vaccine 134612
Biological: meningococcal ACWY (vaccine)
One intramuscular dose.
Active Comparator: Group B
Subjects receiving Mencevax™ ACWY
Biological: Mencevax™ ACWY
One subcutaneous dose.

Detailed Description:

All subjects will have 7 blood samples taken: prior to and one month after vaccination and one, two, three, four and five years after vaccination. No new subjects will be enrolled in the extension phases of this Phase IIb study.

The Protocol Posting has been updated in order to comply with the FDA Amendment Act, September 2007.

  Eligibility

Ages Eligible for Study:   11 Years to 55 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Subjects who the investigator believes that they and/or their parents/ legally acceptable representative can and will comply with the requirements of the protocol.
  • A male or female between, and including, 11 and 55 years of age at the time of vaccination.
  • Written informed consent obtained from the subject/ from the parent or legally acceptable representative of the subject.
  • Free of obvious health problems as established by medical history and clinical examination before entering into the study.
  • Previously completed routine childhood vaccinations to the best of his/her knowledge and/or his/her parents/legally acceptable representative's knowledge.
  • If the subject is female, she must be of non-childbearing potential; or, if of childbearing potential, she must be abstinent or have used adequate contraceptive precautions for 30 days prior to vaccination, and must agree to continue such precautions for two months after completion of the vaccination series. Female subjects in childbearing potential who are not abstinent must have a negative pregnancy test.

Exclusion Criteria:

  • Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the dose of study vaccine, or planned use during the study period.
  • Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the vaccine dose.
  • Planned administration/ administration of a vaccine not foreseen by the study protocol within one month of the dose of vaccine(s).
  • Previous vaccination with meningococcal polysaccharide vaccine of serogroup A, C W and/or Y within the last five previous years.
  • Previous vaccination with meningococcal polysaccharide conjugate vaccine of serogroup A, C W and/or Y.
  • History of meningococcal disease due to serogroup A, C, W or Y.
  • Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection.
  • A family history of congenital or hereditary immunodeficiency.
  • History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.
  • Major congenital defects or serious chronic illness.
  • History of any neurologic disorders or seizures.
  • History of Guillain-Barré syndrome.
  • Acute disease at the time of enrolment.
  • Administration of immunoglobulins and/or any blood products within the three months preceding the first dose of study vaccine or planned administration during the study period.
  • Pregnant or lactating female.
  • History of chronic alcohol consumption and/or drug abuse.
  • Female planning to become pregnant or planning to discontinue contraceptive precautions.

Specific criteria to be checked at each study visit for the long term follow-up:

  • History of meningococcal serogroup A,C, W and Y disease.
  • Administration of a meningococcal polysaccharide or a meningococcal polysaccharide conjugate vaccine not planned in the protocol.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00356369

Locations
Philippines
GSK Investigational Site
Manila, Philippines, 1000
GSK Investigational Site
Muntinlupa, Philippines, 1781
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

Publications:
Borja-Tabora C et al. Persistence of immune response up to 3 years following vaccination with MenACWY-TT Meningococcal vaccine in subjects aged 11-55 years. Abstract presented at the Northern European Conference on Travel Medicine (NECTM), Dublin, Ireland, 6-8 June 2012.

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT00356369     History of Changes
Obsolete Identifiers: NCT00356538, NCT00356577, NCT00356499, NCT00356694, NCT00356876
Other Study ID Numbers: 107386, 107392 (Ext: Y1), 107398 (Ext: Y2), 107402 (Ext: Y3), 107404 (Ext: Y4), 107406 (Ext: Y5)
Study First Received: July 25, 2006
Last Updated: March 28, 2013
Health Authority: Philippines: Institutional Review Board

Keywords provided by GlaxoSmithKline:
Immunogenicity
Healthy
Persistence
Meningococcal vaccine
Non-inferiority
Meningococcal A C W Y Diseases
meningococcal serogroups A, C, W & Y diseases

Additional relevant MeSH terms:
Meningococcal Infections
Neisseriaceae Infections
Gram-Negative Bacterial Infections
Bacterial Infections

ClinicalTrials.gov processed this record on July 24, 2014